Mandate

Vinge advises IRLAB Therapeutics in connection with a directed share issue

May 24, 2018

The board of directors of IRLAB Therapeutics has, on the basis of an authorisation granted from the annual general meeting, resolved on a directed new issue of shares, whereby IRLAB Therapeutics will raise proceeds of SEK 138,6 million, before issue costs.

The share issue is directed to a number of selected institutional investors in Sweden and the US. 
 
IRLAB Therapeutics is a research and development company, listed on Nasdaq First North Premier, focused on development of novel therapies for the treatment of neurodegenerative diseases, in particular Parkinson’s disease and dementia.
 
Vinge’s team has consisted of Dain Hård Nevonen, Sofie Bjärtun and Hampus Olsson
 
 

Related

Vinge advises Spotlight Group in connection with offer from Kriptown

Vinge is advising Spotlight Group AB (publ) in connection with Kriptown SAS having made a public cash takeover offer to the shareholders of Spotlight Group.
June 17, 2026

Vinge has advised EQT IX in connection with its exit of Beijer Ref AB (publ)

Vinge has advised EQT IX (”EQT”) in connection with the sale of all of its remaining shares of series B in Beijer Ref AB (publ) through an accelerated bookbuilding process carried out on 15 June 2026.
June 16, 2026

Vinge has advised Accent Equity VI and the minority shareholders on their divestment of Malte Månson

Vinge has advised Accent Equity VI and the minority shareholders on their divestment of Malte Månson to Citira, a European tire management provider and portfolio company of Norvestor. Headquartered in Stockholm, Malte Månson is an independent service and repair provider for commercial vehicles and operates a network of 28 service workshop locations across Sweden, authorized by brands such as MAN, DAF, IVECO, Mercedes-Benz, Setra, VDL and EVO. Malte Månson has an annual revenue of SEK 800 million and employs over 300 full-time professionals.
June 08, 2026